SanguiBioTech: Revenues Attain USD 133,000 in Financial Year 2014

For its financial year 2014 (ended June 30, 2014) Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD133,470 USD after USD105,487 in the previous financial year. This increase is primarily attributable to royalties on sales of the Granulox wound dressing, marketing and sales of which are out-licensed to SastoMed GmbH, a joint venture company in which Sangui holds a stake of 25%. Revenues in the fourth quarter of the 2014 financial year came in at USD43,729 USD (Q4/2013: USD24,056). Granulox is the first dressing to significantly improve oxygen supply to wounds with poor blood supply and thereby decisively accelerates wound healing.

Research and development expenses increased to USD543,071 (FY 2013: USD65,010). The position includes the purchase of a comprehensive set of clinical data. This also led to the increase of total operating expenses to USD1.4 million (FY 2013: USD1.3 million). The net result attributable to shareholders amounts to minus USD1.4 million up from minus USD2.1 million in the previous financial year when an impairment of receivables in the amount of USD1.0 million had occurred which had been brought in as capital into SastoMed GmbH. Cash outflow from operations in the amount of USD0.8 million (FY 2013: USD0.8 million) and from investing activities in the amount of USD0.2million (FY 2013: USD0,9 million) were offset by an cash inflow from financing of USD0.9 million (FY 2013: USD1.4 million).

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB marketplace (www.otcmarkets.com: SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

- -

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates,” "expects,” "intends,” "plans,” "believes,” "seeks,” "estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.